Back to Search Start Over

Supplementary Tables from ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Authors :
Carlos L. Arteaga
Amparo Ruiz-Simon
Vicente Guillem
Mónica Arnedos
Fabrice André
Stefan Michiels
Mohamed Amine Bayar
Antonio Llombart-Cussac
Ana Lluch
J. Alejandro Perez-Fidalgo
Joaquín Gavilá
Alberto Servetto
Valerie M. Jansen
Monica V. Estrada
Jennifer M. Giltnane
Luis J. Schwarz
Kyung-Min Lee
Daniel G. Stover
Katherine E. Hutchinson
Luigi Formisano
Thomas P. Stricker
Angel L. Guerrero-Zotano
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Supplemental Table S1: The Preoperative Endocrine Prognostic Index (PEPI score) Supplemental Table S2:* Baseline Ki67: 7 patients had missing values Supplemental Table S3a: Driver Mutations Supplemental Table S3b: Driver Copy Number Alterations Supplemental Table S3c: Mutations clinically actionable. Drug prescription Supplemental Table S4: Actionable CNAs. Drug prescription Supplemental Table S5: Overlap between genes upregulated in resistant tumors and transcription factor targets genes Suplemental Table S6: Change from baseline to surgery in gene expressions of the 47 most upregulated genes in the tumors resistant to prolonged neoadjuvant letrozole from 60 HR-positive/HER2-negative breast cancers in POP trial. A decreased gene expression translates into a geometric mean change < 1 . An increased or stable gene expression translates into a geometric mean change {greater than or equal to} 1. Supplemental Table S7: Mutations detected in this study(post-filtering) Supplemental Table S8: Gene expression values (FPKM)

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....1ca888fa00d7bd81556fdcc0a854f431